Market Cap 38.56M
Revenue (ttm) 0.00
Net Income (ttm) -24.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -8.12
Volume 565,300
Avg Vol 557,812
Day's Range N/A - N/A
Shares Out 40.00M
Stochastic %K 3%
Beta 2.79
Analysts Strong Sell
Price Target $7.00

Company Profile

Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel...

Industry: Biotechnology
Sector: Healthcare
Phone: 353 1 903 8354
Address:
3 Dublin Landings, North Wall Quay, Dublin, Ireland
Newmightyduck
Newmightyduck Jul. 8 at 6:45 AM
$ITRM Morning Bulls and Mad Scientists.
0 · Reply
Amb8675309
Amb8675309 Jul. 8 at 4:47 AM
$ITRM on the Coyne filing/ it says “unless promptly” addressed- July 4th holiday and half day of markets- if they file tomorrow or Wednesday that could be seen as “promptly” rectifying late paperwork situation and nothing else happens. Or maybe we get a BO! We will keep finding reasons to speculate about everything we can find- or Corey could do a bit better job at letting us know what our 30/60/90 day Eversana roll out will look like etc. or maybe he’s not talking because there’s a better offer coming!!!!!
1 · Reply
SOLMike
SOLMike Jul. 8 at 2:50 AM
$ITRM under Item 5.02(b)/(c) of the SEC rules starts on the date the triggering event becomes public or internally final and known to the company, whichever is earlier and deemed material. In this case, the June 30 press release announcing Christine Coyne’s appointment as Chief Commercial Officer is the triggering event for the 8-K. The Form 3, dated June 1, is not the relevant date.
1 · Reply
Toptopy
Toptopy Jul. 8 at 2:44 AM
$ITRM To make it clear
1 · Reply
look2theblue
look2theblue Jul. 8 at 1:57 AM
$ITRM It’s highly unusual that the 8-K for her position wasn’t filed by the 5:30 p.m. ET deadline today. This delay, though seemingly minor, could be a signal of a more significant announcement forthcoming. Such a development has the potential to trigger a meaningful rally in the stock tomorrow if word spreads. Let's watch for any early volume signs tomorrow after the open.
3 · Reply
mallanaga
mallanaga Jul. 8 at 12:55 AM
0 · Reply
D1onysus
D1onysus Jul. 8 at 12:54 AM
$ITRM does anyone know how many positions they have officially hired for launch and how many are posted?
0 · Reply
Amb8675309
Amb8675309 Jul. 8 at 12:19 AM
$ITRM just emailed Coyne to see if she’ll comment on launch start date etc. let’s see if we get any communication. 😂
0 · Reply
iambaron
iambaron Jul. 7 at 11:54 PM
$ITRM Tried sending investor relations an email. It bounced back and said the email rejected it. I also just happened to notice that ever since the Eversana partnership Press Release, they no longer included the email and the bottom with contact information. Idk take that how you want since people don’t like theories
1 · Reply
Beansupreeme1
Beansupreeme1 Jul. 7 at 11:54 PM
$ITRM I’m in 😎 Either lambo in Vegas or behind the grill at McD’s
0 · Reply
Latest News on ITRM
Iterum Therapeutics plc (ITRM) Q1 2025 Earnings Call Transcript

May 13, 2025, 1:44 PM EDT - 7 weeks ago

Iterum Therapeutics plc (ITRM) Q1 2025 Earnings Call Transcript


Iterum Therapeutics plc (ITRM) Q4 2024 Earnings Call Transcript

Feb 7, 2025, 10:20 AM EST - 5 months ago

Iterum Therapeutics plc (ITRM) Q4 2024 Earnings Call Transcript


Iterum Therapeutics Regains Full Nasdaq Compliance

Nov 21, 2024, 8:30 AM EST - 8 months ago

Iterum Therapeutics Regains Full Nasdaq Compliance


Iterum Therapeutics plc (ITRM) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 1:14 PM EST - 8 months ago

Iterum Therapeutics plc (ITRM) Q3 2024 Earnings Call Transcript


Iterum Therapeutics Reports Third Quarter 2024 Financial Results

Nov 14, 2024, 7:00 AM EST - 8 months ago

Iterum Therapeutics Reports Third Quarter 2024 Financial Results


US FDA approves Iterum's treatment for urinary infection

Oct 25, 2024, 10:57 AM EDT - 9 months ago

US FDA approves Iterum's treatment for urinary infection


Iterum Therapeutics to Present Data at IDWeek 2024

Oct 10, 2024, 8:30 AM EDT - 9 months ago

Iterum Therapeutics to Present Data at IDWeek 2024


Iterum Therapeutics plc (ITRM) Q2 2024 Earnings Call Transcript

Aug 16, 2024, 11:27 AM EDT - 11 months ago

Iterum Therapeutics plc (ITRM) Q2 2024 Earnings Call Transcript


Iterum Therapeutics Reports Second Quarter 2024 Financial Results

Aug 14, 2024, 7:00 AM EDT - 11 months ago

Iterum Therapeutics Reports Second Quarter 2024 Financial Results


Iterum Therapeutics Commences Rights Offering

Jul 22, 2024, 7:30 AM EDT - 1 year ago

Iterum Therapeutics Commences Rights Offering


Iterum Therapeutics plc (ITRM) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 10:08 AM EDT - 1 year ago

Iterum Therapeutics plc (ITRM) Q4 2023 Earnings Call Transcript


Iterum Therapeutics plc (ITRM) Q3 2023 Earnings Call Transcript

Nov 14, 2023, 10:32 AM EST - 1 year ago

Iterum Therapeutics plc (ITRM) Q3 2023 Earnings Call Transcript


Iterum Therapeutics to Present Data at IDWeek 2023

Oct 12, 2023, 9:15 AM EDT - 1 year ago

Iterum Therapeutics to Present Data at IDWeek 2023


Iterum Therapeutics plc (ITRM) Q2 2023 Earnings Call Transcript

Aug 11, 2023, 9:20 AM EDT - 2 years ago

Iterum Therapeutics plc (ITRM) Q2 2023 Earnings Call Transcript


Iterum Therapeutics to Present Data at ASM Microbe 2023

Jun 12, 2023, 6:23 PM EDT - 2 years ago

Iterum Therapeutics to Present Data at ASM Microbe 2023


Newmightyduck
Newmightyduck Jul. 8 at 6:45 AM
$ITRM Morning Bulls and Mad Scientists.
0 · Reply
Amb8675309
Amb8675309 Jul. 8 at 4:47 AM
$ITRM on the Coyne filing/ it says “unless promptly” addressed- July 4th holiday and half day of markets- if they file tomorrow or Wednesday that could be seen as “promptly” rectifying late paperwork situation and nothing else happens. Or maybe we get a BO! We will keep finding reasons to speculate about everything we can find- or Corey could do a bit better job at letting us know what our 30/60/90 day Eversana roll out will look like etc. or maybe he’s not talking because there’s a better offer coming!!!!!
1 · Reply
SOLMike
SOLMike Jul. 8 at 2:50 AM
$ITRM under Item 5.02(b)/(c) of the SEC rules starts on the date the triggering event becomes public or internally final and known to the company, whichever is earlier and deemed material. In this case, the June 30 press release announcing Christine Coyne’s appointment as Chief Commercial Officer is the triggering event for the 8-K. The Form 3, dated June 1, is not the relevant date.
1 · Reply
Toptopy
Toptopy Jul. 8 at 2:44 AM
$ITRM To make it clear
1 · Reply
look2theblue
look2theblue Jul. 8 at 1:57 AM
$ITRM It’s highly unusual that the 8-K for her position wasn’t filed by the 5:30 p.m. ET deadline today. This delay, though seemingly minor, could be a signal of a more significant announcement forthcoming. Such a development has the potential to trigger a meaningful rally in the stock tomorrow if word spreads. Let's watch for any early volume signs tomorrow after the open.
3 · Reply
mallanaga
mallanaga Jul. 8 at 12:55 AM
0 · Reply
D1onysus
D1onysus Jul. 8 at 12:54 AM
$ITRM does anyone know how many positions they have officially hired for launch and how many are posted?
0 · Reply
Amb8675309
Amb8675309 Jul. 8 at 12:19 AM
$ITRM just emailed Coyne to see if she’ll comment on launch start date etc. let’s see if we get any communication. 😂
0 · Reply
iambaron
iambaron Jul. 7 at 11:54 PM
$ITRM Tried sending investor relations an email. It bounced back and said the email rejected it. I also just happened to notice that ever since the Eversana partnership Press Release, they no longer included the email and the bottom with contact information. Idk take that how you want since people don’t like theories
1 · Reply
Beansupreeme1
Beansupreeme1 Jul. 7 at 11:54 PM
$ITRM I’m in 😎 Either lambo in Vegas or behind the grill at McD’s
0 · Reply
Amb8675309
Amb8675309 Jul. 7 at 11:07 PM
$ITRM So we’ve got lots of shares- of course I’d like $8/9/10/12$ a share all cash BO. Why, after 8 months don’t we have that? Judy admitted they’d gotten lowballs(more than one). At that time I assumed it’s because BP are ruthless & will squeeze the little co. and try to get their IP when they’re out of money. I looked at all angles: institutional $ in ITRM isn’t high because Corey filled that shelf a couple of months ago, they see it and think he’ll dilute/because Corey is short on cash, etc. I’m saying that perhaps the problem is getting all insurers on board to cover Orlynvah without a prior authorization takes time- so it’s not a quick event. So could Coyne be there at the request of a BP buyer? Or is Fishman wanting her to maximize a roll out that, at this moment is just him plus Eversana? All of us have moved the goal posts every month.If there’s no BO soon, it’ll add to my concern that right now, without IRL scripts+insurers on board, it’s just Corey&Eversana😢 still 🙏4all$$$BO
2 · Reply
iambaron
iambaron Jul. 7 at 10:40 PM
$ITRM nice… all your comments are hidden negative comments. I happen to like the theories. Makes me think about other things. He also hasn’t posted a theory and I’m posting some theories and some truth. Weirdo
1 · Reply
gogo66so
gogo66so Jul. 7 at 10:30 PM
$ITRM HighMark, Orlynvah* sulopenem etzadroxil and probenecid Prescriber Discretion https://providers.highmark.com/content/dam/highmark/en/providerresourcecenter/pdfs/all/documents/pdfs/policies-and-programs/formulary-updates/2024/drug-formulary-update-december-2024.pdf
0 · Reply
Curvanord12
Curvanord12 Jul. 7 at 10:29 PM
$ITRM please guys stop I can’t handle another night of SOLmikey’s theories on the delayed filing of the 8K
2 · Reply
iambaron
iambaron Jul. 7 at 10:14 PM
$ITRM blah blah blah whatever give me my money
0 · Reply
DollerADay
DollerADay Jul. 7 at 10:06 PM
$ITRM Yes, the shortened trading day counts as a full day towards the four-day filing requirement. It's a long shot, but one of the circumstances of late filing is balancing YUGE buyout news and related filings. There is an outside chance.
1 · Reply
iambaron
iambaron Jul. 7 at 10:00 PM
$ITRM based on press release and ownership forms there should be a filing. Still looking for her start date as it’s not given.
1 · Reply
iambaron
iambaron Jul. 7 at 9:56 PM
$ITRM They must file within 4 business days following the appointment. My question here is when is the actual appointment? We have an announcement date with the PR but it doesn’t mention her start date. We see she was awarded options 07/01/25. If this is her start date then we would see an 8-K tomorrow. Deep breaths, in and out 🧘 😮😮‍💨
1 · Reply
DollerADay
DollerADay Jul. 7 at 9:56 PM
$ITRM They will have to file a notification of late filing 12b-25 tomorrow. This is a big SOX requirement and unless we are doing the math incorrectly, we will see something in the am. I was hoping for am and not AH...
0 · Reply
look2theblue
look2theblue Jul. 7 at 9:42 PM
$ITRM The fact that the 3rd wasn't a full business day is irrelevant. #3 crossed my mind as well. :-)
1 · Reply
FishinAround
FishinAround Jul. 7 at 9:36 PM
$ITRM Some comments to expectations for 8K filing delay since I don’t see it on the website. 1. Was July 3 a full business day? 2. According to AI, the most material consequence of missing the deadline seems to be Loss of Form S-3 eligibility. Missing an 8-K can disqualify them from using it. Bye bye shelf? 3. If they miss it and don’t care, I’d say that’s a pretty big tell.
1 · Reply
look2theblue
look2theblue Jul. 7 at 9:08 PM
$ITRM Yep, they have until 5:30ET today - SEC rules say 4 days after an Executive level appointment. I want to see favorable change of control language in her package.
2 · Reply